If you have been reading about melanocortin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-16. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
=== Risks === As with the licking of wounds by people, wound licking by animals carries a risk of infection. Allowing pet cats to lick open wounds can cause cellulitis and sepsis due to bacterial infections. Licking of open wounds by dogs could transmit rabies if the dog is infected with rabies, although this is said by the CDC to be rare. Dog saliva has been reported to complicate the healing of ulcers. Another issue is the possibility of an allergy to proteins in the saliva of pets, such as Fel d 1 in cat allergy and Can f 1 in dog allergy. Cases of serious infection following the licking of wounds by pets include:
== Background == KEZAD Group was launched in September 2022 through the consolidation of Khalifa Industrial Zone Abu Dhabi (KIZAD) and ZonesCorp. It was established to expand Abu Dhabi’s economic cities and free zones, offering and streamlining infrastructure development, regulatory frameworks, and investment facilitation.
Refractance window drying (RWD) is a drying technique which uses infrared light to dry food or pharmaceuticals to reduce losses of temperature sensitive and volatile compounds. The nutrient retention in RWD products is comparable to freeze-dried or even fresh produce, while offering greater energy efficiency to other food drying techniques. However, RWD is not suited for large-scale production as the conveyor belt thickness is a compromise between thermal conductivity and mechanical strength.
=== Individual and community well-being === The distinction between individual and community well-being is central to understanding how societies flourish at different levels and for evaluating trade-offs in policy decisions. Individual well-being concerns the quality of life of a particular person and is the main focus of disciplines such as psychology and some schools of philosophy. Community well-being applies the concept of well-being to a group of people. It encompasses a broad range of economic, social, environmental, and cultural aspects that influence how the community functions and thrives while ensuring that the community's needs are fulfilled. One view sees community well-being as the sum of the degrees of the well-being of each individual, while others emphasize that the relation between the two is more complex. Individual and community well-being often support each other. For instance, high individual well-being can lead a person to contribute more to their community, and a well-functioning community can make its members happy. However, there can also be tensions, like when changes necessary for community well-being conflict with the individual well-being of certain members. Closely related to community well-being are categories defined for specific demographic groups. For instance, child well-being is about the quality of life of children, including factors such as health, education, material security, and social development in a loving and nurturing environment. Other examples include women's, elderly, student, and employee well-being.
Grave fields are one of the chief sources of information on prehistoric cultures, and numerous archaeological cultures are labelled and defined by their burial customs, such as the Urnfield culture of the European Bronze Age.
Sources: en.wikipedia.org
== Analysis == The analysis of YTXs is necessary because of the possible health risks and the limits put in place by the European Commission directive. It is complex due to the large number of YTX analogues that can be present in the sample. Analysis is also problematic because YTXs have similar properties to other lipophilic toxins present in the samples, so methods can be subject to false negative or false positive results due to sample interferences. Several experimental techniques have been developed to detect YTXs, each offering varying levels of selectivity and sensitivity, whilst having numerous advantages and disadvantages.
== External links == GeneReviews/NCBI/NIH/UW entry on Chondrodysplasia Punctata 2, X-Linked, Conradi-Hünermann Syndrome, Happle Syndrome EBP+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
condosity A comparative measurement of the electrical conductivity of a solution defined as the molar concentration of a sodium chloride (NaCl) solution that has the same specific electrical conductance as the solution under test. It is typically expressed in units of moles per litre (or per some other unit of volume).
Erratic dimming and strong infrared emission are attributed to hot debris produced by the impact passing in front of the star. 12 March – An international team reports the first direct measurements of the nanomechanical properties of lithium dendrites, microscopic needle-like structures that can form inside lithium batteries and cause them to short circuit or catch fire. The study finds that dendrites are strengthened by a solid electrolyte interphase layer, making them brittle and capable of penetrating battery separators, providing new insight into battery degradation and safety risks. 17 March – Physicists at CERN's LHCb experiment report the discovery of the doubly charmed baryon Ξcc⁺. The particle, containing two charm quarks and one down quark, is detected with high statistical significance and resolves a long-standing discrepancy from earlier experimental results. 18 March – Charles H. Bennett and Gilles Brassard are awarded the 2025 Turing Award for their work in quantum information science. 20 March – Scientists from Great Ormond Street Hospital and University College London report the creation of the first lab‑grown oesophagus, and show it can safely replace a full section of the organ and restore normal function, including swallowing, in a growing animal without the need for immunosuppression. 24 March Antimatter particles are transported by road for the first time, to assess their stability during transit. An estimated 100 to 1,000 antiprotons are carried in a Penning trap across a distance of five kilometres in Switzerland.
Sources: en.wikipedia.org
meaning one infectious person on average infects 0.4 susceptible people per day and recovers in 1/0.2=5 days. Thus when this person recovered, there are two people still infectious directly got from this person and
=== Education === Humphreys graduated from Chickasha High School (Chickasha, Oklahoma) in 1948. He then attended Colorado College, graduating with his BA in 1952. He attended Seabury-Western Theological Seminary (in Evanston, Illinois), graduating with the MDiv degree in 1955. In 1965, he entered graduate school at Washington University to pursue a PhD in sociology. His dissertation adviser was Lee Rainwater. Humphreys obtained two pre-doctoral research fellowships from the National Institute of Mental Health to fund his dissertation research. He completed his dissertation in 1968, graduating with his PhD in that year. He published the dissertation as Tearoom Trade: Impersonal Sex in Public Places in 1970. His book won the C. Wright Mills Award from the Society for the Study of Social Problems in 1969. Due to the controversy around his research methods and the topic of his research, there was a failed attempt by the chancellor of Washington University to rescind his PhD.
Fission cross sections are a measurable property related to the probability that fission will occur in a nuclear reaction. Cross sections are a function of incident neutron energy, and those for 235U and 239Pu are a million times higher than 238U at lower neutron energy levels. Absorption of any neutron makes available to the nucleus binding energy of about 5.3 MeV. 238U needs a fast neutron to supply the additional 1 MeV needed to cross the critical energy barrier for fission. In the case of 235U however, that extra energy is provided when 235U adjusts from an odd to an even mass. In the words of Younes and Lovelace, "...the neutron absorption on a 235U target forms a 236U nucleus with excitation energy greater than the critical fission energy, whereas in the case of n + 238U, the resulting 239U nucleus has an excitation energy below the critical fission energy." About 6 MeV of the fission-input energy is supplied by the simple binding of an extra neutron to the heavy nucleus via the strong force; however, in many fissionable isotopes, this amount of energy is not enough for fission. Uranium-238, for example, has a near-zero fission cross section for neutrons of less than 1 MeV energy. If no additional energy is supplied by any other mechanism, the nucleus will not fission, but will merely absorb the neutron, as happens when 238U absorbs slow and even some fraction of fast neutrons, to become 239U.
== Interactions == HLA-G has been shown to interact with CD8A. When in its soluble form, HLA-G interacts with Ig-like transcript 2 (ILT2), a leukocyte receptor. When it is membrane bound, it interacts with Ig-like transcript 4 (ILT4). Soluble HLA-G can bind to KIR2DL4, which is often found on the surface of natural killer cells. The identity of the peptide presented by HLA-G is unrelated to the binding of HLA with KIR2DL4, ILT2, or ILT4. Because HLA-G interacts with receptors using a variety of its domains, multiple antibodies are necessary to inhibit all of its functions. Both ILT2 and ILT4 cause negative intracellular signaling. In monocytes, binding to either ILT2 or ILT4 receptors cause the inhibition of monocyte/macrophage mediated toxicity. In dendritic cells, binding to both receptors can prevent dendritic cells from maturing and prevent the activation of T cells. Additionally, HLA-G may interact with ILT4 receptors on the surface of neutrophils to inhibit phagocytosis. In natural killer cells, HLA-G binds with the ILT2 receptor to inhibit the secretion of IFN-γ, a cytokine that can activate macrophages and stimulate natural killer cells and neutrophils. HLA-G binds to ILT2 on B cells to cause the inhibition of B cell proliferation, differentiation, and the secretion of antibodies. It binds to ILT2 on T cells to downregulate T cell chemokine expression. The cytokine expression of T cells mimics that of TH2 cells. HLA-G causes apoptosis in CD8+ T cells. All together these effects serve to decrease the inflammatory response of the immune system.
In addition to arthropods, marine animals also contain nitrile compounds. These include bursatellin from broad-footed snails of the genus Bursatella and the calyculins isolated from sponges. The albanitriles from sponges of the genus Mycale are linear compounds (chain length 16 to 18 carbon atoms) bearing a nitrile group at one or both termini and several additional C≡C triple bonds.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.